Published in Cancer Res on March 15, 1992
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol (1997) 1.67
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol (2014) 1.19
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status. Br J Cancer (1994) 1.11
Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer (1994) 1.08
The genomics and genetics of endometrial cancer. Adv Genomics Genet (2012) 1.03
K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mol Pathol (1999) 0.97
Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One (2010) 0.93
PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol (2003) 0.87
Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer (1996) 0.86
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol (2006) 0.84
Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol (1997) 0.83
Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Arch (2008) 0.79
Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. Int J Clin Oncol (2011) 0.79
Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch (2005) 0.79
Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br J Cancer (2003) 0.77
Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol (1998) 0.77
Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol (1997) 0.77
Disparities in Gynecological Malignancies. Front Oncol (2016) 0.75
Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium. Gynecol Oncol Case Rep (2012) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med (1999) 9.16
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A (2000) 3.61
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Pneumatosis intestinalis. Surgical management and clinical outcome. Ann Surg (1990) 2.78
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 2.67
Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol (1998) 2.65
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res (1990) 2.55
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 2.43
Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res (1986) 2.37
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol (2000) 2.34
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst (1997) 2.30
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol (1999) 2.25
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res (2001) 2.22
Genetic instability of microsatellites in endometrial carcinoma. Cancer Res (1993) 2.20
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Identification of a new virulence locus in Agrobacterium tumefaciens that affects polysaccharide composition and plant cell attachment. J Bacteriol (1987) 2.08
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain). Virology (1983) 2.06
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide. Radiat Res (1997) 2.02
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol (1999) 1.99
Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res (1992) 1.93
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc Natl Acad Sci U S A (1993) 1.84
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res (1984) 1.83
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene (1999) 1.81
Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet (1994) 1.81
Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol (1998) 1.81
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res (2000) 1.81
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology (2008) 1.80
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer (1999) 1.73
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med (1988) 1.67
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol (1996) 1.66
BCG and cancer. N Engl J Med (1974) 1.66
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol (1999) 1.66
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res (1995) 1.62
CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 1.61
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol (1993) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60